文献速递眼底病与葡萄膜炎

抗胆碱能药物使用与晚期年龄相关性黄斑变性风险的关联

Association of Anticholinergic Drug Use With Risk for Late Age-Related Macular Degeneration.
PubMed 文献 · JAMA Ophthalmol · 2018-01-01

这项在法国4个眼科中心开展的多中心病例对照研究纳入200例晚期年龄相关性黄斑变性(AMD)患者和200例对照,发现曾使用抗胆碱能药物(ACD)至少3个月与晚期AMD风险升高相关(校正OR 2.84,95%CI 1.33-6.06,P=0.007),且高抗胆碱能负荷评分和最长累积暴露年限呈现剂量效应关联;作者指出需要进一步研究尤其是纵向设计来确认这一关联。

要点

  • 曾使用ACD至少3个月与晚期AMD风险升高相关,校正OR 2.84(95%CI 1.33-6.06,P=0.007)。
  • 抗胆碱能负荷评分≥3者校正OR 6.42(95%CI 1.38-29.92,P=0.02)。
  • ACD累积暴露≥15年者校正OR 5.88(95%CI 1.22-28.31,P=0.03),提示剂量效应关联。

核心结论

  • 晚期AMD风险可能随使用ACD至少3个月而升高,且长期使用和高抗胆碱能负荷评分提示剂量效应关联,作者认为需要进一步研究尤其是纵向设计来确认这一关联。

研究设计与样本

  • 多中心病例对照研究,在法国4个眼科中心纳入200例晚期AMD病例和200例对照,入组时间为2016年7月至2017年6月。
  • 暴露定义为AMD诊断前开始使用ACD至少3个月,通过专门访谈记录,并探索累积暴露时长和抗胆碱能负荷评分的剂量效应关联。
  • 采用多变量逻辑回归分析校正年龄、性别、吸烟状态、AMD家族史、饮酒以及抗凝药和抗炎药使用,估计OR和95%CI。

主要发现

  • 病例组平均(SD)年龄74.8(9.2)岁,女性129例(64.5%),白人192例(96%),地图样萎缩65例(32.5%),新生血管性AMD 135例(67.5%),单侧AMD 116例(58%),双侧AMD 84例(42%)。
  • 对照组平均(SD)年龄75.5(7.2)岁,女性116例(58%),白人187例(93.5%)。
  • 病例组26例(13%)和对照组10例(5%)在AMD发病前至少3个月有终生ACD暴露。
  • 曾暴露于ACD与AMD风险升高相关(校正OR 2.84;95%CI 1.33-6.06;P=0.007)。
  • 高抗胆碱能负荷评分(≥3)与AMD风险升高相关(校正OR 6.42;95%CI 1.38-29.92;P=0.02),最长累积ACD暴露(≥15年)与AMD风险升高相关(校正OR 5.88;95%CI 1.22-28.31;P=0.03)。

关键数值与推荐

  • 晚期AMD定义为至少1眼存在新生血管性AMD特征或视网膜色素上皮地图样萎缩。
  • ACD暴露定义为AMD诊断前开始使用至少3个月。
  • 抗胆碱能负荷评分≥3为高负荷组。
  • 最长累积ACD暴露≥15年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要进一步研究,尤其是纵向设计研究,来确认这一关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Amyloid-β is a major component of retinal drusen, the primary lesions of age-related macular degeneration (AMD), and autopsy and animal models suggested that anticholinergic drug (ACD) use increased brain amyloid-β deposition. OBJECTIVE: To investigate the association between exposure to ACDs and late AMD (features of neovascular AMD or geographic atrophy of the retinal pigment epithelium in at least 1 eye). DESIGN, SETTING AND PARTICIPANTS: A multicenter case-control study in 4 French ophthalmologic centers comprising 200 cases with late AMD and 200 controls enrolled from July 2016 to June 2017. EXPOSURES: Exposure to at least 3 months of ACDs started before AMD diagnosis was recorded during a specific interview. A dose-effect association with cumulative exposure duration and Anticholinergic Burden Score was explored. The association between ACD exposure and AMD was assessed by multivariate logistic regression analysis adjusted for age, sex, smoking status, family history of AMD, alcohol consumption, and use of anticoagulant and anti-inflammatory drugs. Odds ratios (ORs) and 95% confidence intervals were estimated. MAIN OUTCOMES AND MEASURES: Association between exposure to ACDs and late AMD. RESULTS: Among case participants, the mean (SD) age was 74.8 (9.2) years, 129 (64.5%) were women, 192 (96%) were white, 65 (32.5%) had geographic atrophy, 135 (67.5%) had neovascular AMD, 116 (58%) had unilateral AMD, and 84 (42%) had bilateral AMD. Among control participants, the mean (SD) age was 75.5 (7.2) years, with 116 (58%) women and 187 (93.5%) white participants. Twenty-six cases (13%) and 10 controls (5%) were exposed to ACDs throughout life for at least 3 months before AMD onset. Risk of AMD was increased with ever exposure to ACDs (adjusted OR [aOR], 2.84; 95% CI, 1.33-6.06; P = .007), high Anticholinergic Burden Score (≥3) (aOR, 6.42; 95% CI, 1.38-29.92; P = .02), and longest cumulative exposure to ACD (≥15 years) (aOR, 5.88; 95% CI, 1.22-28.31; P = .03). CONCLUSIONS AND RELEVANCE: Risk of late AMD may be increased with at least 3 months' use of ACDs. A dose-effect association was suggested by a greater association with prolonged use and high Anticholinergic Burden Score. Further studies, in particular those with longitudinal design, are needed to confirm this association.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Aldebert G, Faillie JL, Hillaire-Buys D, et al. Association of Anticholinergic Drug Use With Risk for Late Age-Related Macular Degeneration. JAMA Ophthalmol. 2018. PMID: 29800005. doi:10.1001/jamaophthalmol.2018.1719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。